CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 361 enrolled
Drug / intervention
LY2189265 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01584232
NCT01584232Phase 3Completed
CompareCT.gov

A Phase 3 Study of LY2189265 Compared to Insulin Glargine in Patients With Type 2 Diabetes Mellitus on a Sulfonylurea and/or Biguanide

Eli Lilly and Company·interventional·Posted Apr 24, 2012·Updated Oct 20, 2014

In Brief

A Phase 3 clinical trial evaluating LY2189265, Insulin glargine, and 2 other interventions for Type 2 Diabetes Mellitus. Completed, enrolled 361 participants across 15 sites.

Detailed Summary

The purpose of this trial is to examine the efficacy and safety of once-weekly LY2189265 (dulaglutide) in participants with type 2 diabetes mellitus taking an oral antihyperglycemic medication (OAM).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 24, 2012
Enrollment StartApr 1, 2012
Primary CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 14.2 years ago

Interventions

LY2189265drug

Insulin glarginedrug

Sulfonylureas (SU)drug

Biguanide (BG)drug